At the recent ASCO 2016 Genitourinary Cancers Symposium (ASCO GU) that took place in San Francisco the week before the JP Morgan Healthcare Conference (JPM), one of the noteworthy presentations was on a novel target for men with advanced prostate cancer.
While JPM may have been a “dud” for many, several companies did take the opportunity to update and discuss their corporate strategy going into 2016, which gave a surprising amount to comment on in our 3 blog posts from the meeting: JPM Day 1, JPM Day 2, JPM Day 3.
In this post we look at the “take homes” from the ASCO GU presentation, and what looks like it could be a new race to market.
It’s good to see novel targets for men with advanced prostate cancer, and potential new treatment options on the horizon!
Subscribers can login to read more or you can purchase access below.